13 C NMR (150.9 MHz, D6-DMSO): δ [ppm] = 157.4 (C q, arom ), 148.4 (C q, arom ), 148.3 (C q, arom ), 141.8 (C q, arom ), 132.1 (CH arom ), 130.1 (CH arom ), 128.8 (CH arom ), 126.3 (C q, arom ), 125.5 (CH arom ), 123.6 (CH arom ), 123.0 (C q. arom ), 112.5 (CH arom ), 62.0(CH 2 ), 14.1 (CH 3 ).
[6-(2-Nitrophenyl)imidazo[2,1-b]thiazol-3-yl]methanol (8)
6-(2-nitrophenyl)-imidazo[2,1-b]thiazole-3-carboxylic acid ethyl ester (7) (200 mg, 0.63 mmol) was dissolved in 3 mL DCM (abs.) under argon atmosphere and cooled to -78°C. Then 1 M DIBAL-H in DCM (1.3 mL, 1.26 mmol) was added slowly over 30 min to the stirring reaction mixture. The reaction mixture was stirred at -78 °C for 1 h, quenched with aqueous saturated NH 4 Cl solution and warmed to room temperature. The white solid was removed by filtration, the resulting solution was separated between water and DCM and the aqueous layer was extracted with DCM (2x 15 mL). The combined organic layers were washed with brine, dried with Na 2 SO 4 and concentrated under reduce pressure. The resulting crude product was purified by silica gel column chromatography (heptane/ethyl acetate/methanol 8:8:1) to afford 118 mg of 6-(2-nitrophenyl)imidazo[2,1-b]thiazol-3-yl]methanol (8) as a yellow crystalline solid (68%). 
HRMS (ESI(+)-MS

4-[6-(2-Nitrophenyl)imidazo[2,1-b]thiazol-3-ylmethyl] piperazine-1-carboxylic acid tert-butyl ester (10a)
3-(chloromethyl)-6-(2-nitrophenyl)imidazo[2,1-b]thiazole (9) (800 mg, 2.72 mmol) was dissolved in 8 mL of DMF and Boc-piperazine (760 mg, 4.08 mmol), K 2 CO 3 (1.13 g, 8.20 mmol) as well as a catalytic amount of NaI were added. The resulting mixture was stirred at room temperature overnight, filtered and concentrated under reduce pressure. The resulting crude product was purified by silica gel column chromatography (heptane/ethyl acetate 1:1) to afford 798 mg of 4-[6-(2-nitrophenyl)imidazo[2,1-b]thiazol-3-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester (10a) as a yellow crystalline solid (66%). 
HRMS (ESI(+)-MS
3-((1H-Imidazol-1-yl)methyl)-6-(2-nitrophenyl)imidazo [2,1-b]thiazole (10b)
Essentially the same procedure as the preparation of4-[6-(2-nitrophenyl)imidazo[2,1-b]thiazol-3-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester (10a) was employed.
3-(chloromethyl)-6-(2-nitrophenyl)imidazo[2,1-b]thiazole (9) (100 mg, 0.34 mmol) in 1.5 mL of DMF, imidazole (46 mg, 0.68 mmol), K 2 CO 3 (141 mg, 1.02 mmol) and a catalytic amount of NaI were used.
Yield: 70 mg (65%; yellow crystalline solid). was added to the solution and the reaction mixture was stirred at 78 °C for 30 min. After removal of the solvent under reduced pressure, the residue was dissolved in 100 mL of ethyl acetate and washed with 40% aqueous K 2 CO 3 solution, water, brine and dried with Na 2 SO 4 before it was concentrated under reduce pressure. The resulting yellowbrown crystalline crude product was purified by silica gel column chromatography (heptane/ethyl acetate 1:2 heptane/ethyl acetate/methanol 2:4:1) to afford 513 mg of 4-[6-(2-aminophenyl)imidazo[2,1-b]thiazol-3-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester (11a) as a colorless crystalline solid (71%). Imidazol-1-yl) 13 C NMR (150.9 MHz, D6-DMSO): δ [ppm] = 147.4 (C q, arom ), 147.3 (C q, arom ), 145.8 (C q, arom ), 137.5 (CH arom ), 128.0 (CH arom ), 127.7 (C q, arom ), 127.4 (CH arom ), 127.0 (CH arom ), 120.1 (CH arom ), 116.0 (CH arom ), 115.9 (C q, arom ), 115.7 (CH arom ), 112.3 (CH arom ), 107.7 (CH arom ), 42.4 (CH 2 ). 3-((1H-Imidazol-1-yl)methyl)imidazo[2,1-b] thiazol-6-yl)phenyl)quinoxaline-2-carboxamide (1b) 2-(3-((1H-imidazol-1-yl)methyl)imidazo[2,1-b]thiazol-6-yl)aniline (11b) (36 mg, 0.11 mmol) and 2-quinoxalinecarboxylic acid (20 mg, 0.11 mmol) were dissolved in 2 mL of DMF and collidine (0.05 mL, 0.33 mmol) was added. The reaction mixture was cooled to 0°C, HATU (50 mg, 0.13 mmol) was added and it was stirred for 1 h at 0°C. After warming to room temperature and stirring for 16 h, the reaction was quenched with aqueous NaHCO 3 (sat.), extracted with DCM (3 x 5 mL), washed with brine, dried with Na 2 SO 4 and concentrated under reduced pressure. The resulting light-brown crystalline crude product was purified by silica gel column chromatography (heptane/ethyl acetate/MeOH 4:4:1) to afford 36 mg of N- (2-(3-((1H-imidazol-1-yl) Essentially the same procedure as the preparation of N-(2-(3-((1H-imidazol-1-yl)methyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide (1b) was employed.
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4-[6-(2-aminophenyl)imidazo[2,1-b]thiazol-3-ylmethyl]piperazine-1-carboxylic acid tert-butyl ester (11a) (50 mg, 0.12 mmol) and 3,5-difluorobenzoic acid (20 mg, 0.12 mmol) in 2 mL of DMF, collidine (0.05 mL, 0.36 mmol) and HATU (60 mg, 0.15 mmol) were used.
Column chromatography: (heptane/ethyl acetate 1:1); than it was dissolved in 2 mL of TFA and stirred at room temperature for 90 min. The reaction mixture was concentrated under reduced pressure, dissolved in 1 mL of H 2 O/ 1 mL of DCM and quenched with 1 mL of aqueous NaHCO 3 solution (sat.). The desired product was then extracted with DCM (3x 2 mL), washed with brine, dried with Na 2 SO 4 and concentrated under reduced pressure to afford 29 mg of 3,5-difluoro-N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)benzamide (2a) as a light-yellow crystalline solid (53 %). 
HRMS (ESI(+)-MS
